ACOR News and Press, Acorda Therapeutics Inc. From 05/02/19

INBRIJA™ (levodopa inhalation powder) commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA 1Q 2019 net sales of $1.3 million; approximate...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (internat...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food an...

Acorda Therapeutics, Inc. (NASDAQ: ACOR ) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months. “We thank Andrew for his many contributions to Acorda over the past five years. One of his first achievements was helpi...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Oppenheimer & Co. Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST. A live audio webcast of the presentation can be accessed under “...

LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of Acorda Therapeutics, Inc. (NASDAQ: ACOR ) investors concerning the Company and its directors’ and officers’ possible violations...

First and Only FDA-Approved Inhaled Levodopa for On-demand Use for OFF Periods in People with Parkinson’s Taking Carbidopa/Levodopa Acorda Therapeutics, Inc. (NASDAQ: ACOR ) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved ...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference on Monday, March 11 at 1:30PM EST. A live audio webcast of the presentation can be accessed unde...

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST. A live audio webcast of the presentation can be accessed under “Investor...

Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella – Executive Director-Investor Relations Ron Cohen – Chief Executive Officer Conference Call Participants Cory Kasimov – JP M...